Cellmid Ltd (CDY):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cellmid Ltd (CDY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12347
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cellmid Ltd (Cellmid), formerly Medical Therapies Ltd, is a life sciences company that develops and commercializes diagnostic and therapeutic products. The company holds comprehensive portfolio of intellectual property relating to the novel targets midkine and FGF5. It offers products such as midkine ELISA kit, advangen international hair loss products and evolis products. Cellmid develops CAB102, a humanized monoclonal antibody for use in solid tumors; CAB101, a monoclonal antibody for the treatment of kidney injury, and inflammatory and fibrotic diseases; and CMK103, a recombinant human form of MK protein for use in cardiac ischemia. The company markets its products in Australia and Japan. Cellmid is headquartered in Sydney, New South Wales, Australia.

Cellmid Ltd (CDY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cellmid Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cellmid Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cellmid Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cellmid Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cellmid Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Cellmid Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cellmid Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Fujikura Kasei Exercises Option For Licensing Agreement With Cellmid For Anti-Midkine Diagnostic Antibodies 11
Equity Offering 12
Cellmid Raises USD0.7 Million in Share Purchase Plan of Shares 12
Cellmid Raises USD1.3 Million in First Tranche of Private Placement of Shares 13
Cellmid to Raise USD5.4 Million in Second Tranche of Private Placement of Shares 14
Cellmid to Raise USD0.8 Million in Private Placement of Shares 15
Cellmid Raises USD3.19 Million in Private Placement of Shares 16
Cellmid Raises USD2.4 Million in First Tranche of Private Placement of Shares 17
Cellmid Completes Private Placement Of Shares For US$1.8 Million 18
Cellmid Completes Private Placement Of Shares For US$2 Million 19
Cellmid Completes Private Placement Of Shares For US$0.3 Million 20
Acquisition 21
Cellmid Completes Acquisition Of Advangen, Biotech Company, For US$1.2 Million 21
Cellmid Ltd – Key Competitors 23
Cellmid Ltd – Key Employees 24
Cellmid Ltd – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Jul 31, 2018: Cellmid notes to the appendix 4c–growing consumer health sales drive revenue uplift 26
Sep 27, 2017: Cellmid’s FY2017 Results Presentation 28
Corporate Communications 29
Oct 16, 2017: Cellmid Appoints Dr Martin Cross as Non-executive Director 29
Legal and Regulatory 30
Nov 02, 2018: Ikon legal action – decision handed down 30
Product News 31
Mar 02, 2017: Cellmid’s FGF5 Inhibitor Clinical Study Published 31
Other Significant Developments 32
Nov 19, 2018: Cellmid appoints exclusive New Zealand distributor 32
May 29, 2018: Cellmid announces Change of Address 33
Jan 09, 2018: Cellmid Quarterly Operational Update 34
Oct 25, 2017: Cellmid: Notes to the Appendix 4C 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Cellmid Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Cellmid Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cellmid Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cellmid Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cellmid Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Cellmid Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Cellmid Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Fujikura Kasei Exercises Option For Licensing Agreement With Cellmid For Anti-Midkine Diagnostic Antibodies 11
Cellmid Raises USD0.7 Million in Share Purchase Plan of Shares 12
Cellmid Raises USD1.3 Million in First Tranche of Private Placement of Shares 13
Cellmid to Raise USD5.4 Million in Second Tranche of Private Placement of Shares 14
Cellmid to Raise USD0.8 Million in Private Placement of Shares 15
Cellmid Raises USD3.19 Million in Private Placement of Shares 16
Cellmid Raises USD2.4 Million in First Tranche of Private Placement of Shares 17
Cellmid Completes Private Placement Of Shares For US$1.8 Million 18
Cellmid Completes Private Placement Of Shares For US$2 Million 19
Cellmid Completes Private Placement Of Shares For US$0.3 Million 20
Cellmid Completes Acquisition Of Advangen, Biotech Company, For US$1.2 Million 21
Cellmid Ltd, Key Competitors 23
Cellmid Ltd, Key Employees 24
Cellmid Ltd, Subsidiaries 25

List of Figures
Cellmid Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cellmid Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cellmid Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cellmid Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cellmid Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cellmid Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Cellmid Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cellmid Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cellmid Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Cellmid Ltd (CDY):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Caleres Inc (CAL):企業の財務・戦略的SWOT分析
    Caleres Inc (CAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Kane Biotech Inc (KNE):企業の財務・戦略的SWOT分析
    Summary Kane Biotech Inc (Kane Biotech) is a biotechnology company which focuses on research, development and commercialization of novel products that prevent and remove biofilm related infections in humans and animals. The company’s products include StrixNB and Vetradent water additive, oral spray, …
  • MORRE-TEC Industries, Inc.:企業の戦略・SWOT・財務情報
    MORRE-TEC Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary MORRE-TEC Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Cavion LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Cavion LLC (Cavion), formerly Tau Therapeutics LLC is a clinical stage pharmaceutical company that develops modulators and drugs. The company researches and develops T-type calcium channel (Cav3) inhibitors for the treatment of neurologic and oncologic diseases. It provides pipeline products …
  • Michael J Fox Foundation for Parkinson’s Research:製薬・医療:M&Aディール及び事業提携情報
    Summary Michael J Fox Foundation for Parkinson's Research (Michael J. Fox) is a research foundation that conducts research on Parkinson's disease. The foundation offers research and development of therapies. It provides drug development and other research activities. Michael J. Fox offers treatments …
  • Quadrise Fuels International Plc (QFI)-石油・ガス分野:企業M&A・提携分析
    Summary Quadrise Fuels International Plc (QFI), formerly Zareba Plc, is an oil-in-water emulsified fuel developer that manufactures and markets MSAR (Multiphase Superfine Atomised Residue), an emulsion fuel as a low cost substitute for conventional heavy fuel oil (HFO) for use in power generation pl …
  • Compania Espanola de Petroleos SAU:企業の戦略的SWOT分析
    Compania Espanola de Petroleos SAU - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Boiron SA:企業の戦略・SWOT・財務情報
    Boiron SA - Strategy, SWOT and Corporate Finance Report Summary Boiron SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Antero Resources Corp (AR):企業の財務・戦略的SWOT分析
    Antero Resources Corp (AR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • INRIX, Inc.:企業の戦略・SWOT・財務情報
    INRIX, Inc. - Strategy, SWOT and Corporate Finance Report Summary INRIX, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • The Saudi Arabian Monetary Agency:企業の戦略的SWOT分析
    The Saudi Arabian Monetary Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Shiseido Co Ltd (4911):企業の財務・戦略的SWOT分析
    Shiseido Co Ltd (4911) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Vifor Pharma AG-製薬・医療分野:企業M&A・提携分析
    Summary Vifor Pharma AG (Vifor Pharma), a subsidiary of Galenica Ltd is a healthcare service provider that discovers, develops, manufactures, and commercializes prescription and over the counter pharmaceutical products for the treatment of iron replacement therapy. The company offers products for tr …
  • RPM International Inc:戦略・SWOT・企業財務分析
    RPM International Inc - Strategy, SWOT and Corporate Finance Report Summary RPM International Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Suzlon Energy Ltd (SUZLON):企業の財務・戦略的SWOT分析
    Suzlon Energy Ltd (SUZLON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Carraro Spa:企業の戦略・SWOT・財務情報
    Carraro Spa - Strategy, SWOT and Corporate Finance Report Summary Carraro Spa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Spectris Plc (SXS):企業の財務・戦略的SWOT分析
    Spectris Plc (SXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Alfa Group Consortium:企業の戦略的SWOT分析
    Alfa Group Consortium - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Stemcor Global Holdings Ltd:企業の戦略・SWOT・財務情報
    Stemcor Global Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Stemcor Global Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Innate Pharma SA (IPH):企業の財務・戦略的SWOT分析
    Summary Innate Pharma SA (Innate Pharma) is a biotechnology company developing antibodies to treat cancer by harnessing the immune system. It offers Lumoxiti, a CD22-directed immunotoxin for the treatment of relapsed or refractory hairy cell leukemia (HCL). The company is investigating drugs against …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆